20461382

Source:http://linkedlifedata.com/resource/pubmed/id/20461382

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0030705, umls-concept:C0034656, umls-concept:C0039938, umls-concept:C0205195, umls-concept:C0235974, umls-concept:C0282460, umls-concept:C0346647, umls-concept:C0449258, umls-concept:C0877373, umls-concept:C1999216
pubmed:issue	3
pubmed:dateCreated	2011-2-22
pubmed:databankReference	http://linkedlifedata.com/resource/pubmed/xref/ClinicalTrials.gov/NCT00177242
pubmed:abstractText	This study evaluated PX-12, a novel small molecule inhibitor of the proto-oncogene (Trx-1), in patients with previously treated advanced pancreatic cancer (APC).
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/P01 CA109552, http://linkedlifedata.com/resource/pubmed/grant/R44CA075923
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7806519
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine, http://linkedlifedata.com/resource/pubmed/chemical/Disulfides, http://linkedlifedata.com/resource/pubmed/chemical/IV 2 compound, http://linkedlifedata.com/resource/pubmed/chemical/Imidazoles, http://linkedlifedata.com/resource/pubmed/chemical/TXN protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Thioredoxins, http://linkedlifedata.com/resource/pubmed/chemical/gemcitabine
pubmed:status	MEDLINE
pubmed:month	Mar
pubmed:issn	1432-0843
pubmed:author	pubmed-author:AbbruzzeseJamesJ, pubmed-author:BakerAmanda FAF, pubmed-author:DragovichTomislavT, pubmed-author:GreenSylvanS, pubmed-author:GuillenJose MJM, pubmed-author:KirkpatrickLynnL, pubmed-author:PestanoLinda ALA, pubmed-author:RamanathanRamesh KRK, pubmed-author:Von HoffDaniel DDD
pubmed:issnType	Electronic
pubmed:volume	67
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	503-9
pubmed:meshHeading	pubmed-meshheading:20461382-Adult, pubmed-meshheading:20461382-Aged, pubmed-meshheading:20461382-Aged, 80 and over, pubmed-meshheading:20461382-Antineoplastic Agents, pubmed-meshheading:20461382-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:20461382-Deoxycytidine, pubmed-meshheading:20461382-Disease Progression, pubmed-meshheading:20461382-Disease-Free Survival, pubmed-meshheading:20461382-Disulfides, pubmed-meshheading:20461382-Dose-Response Relationship, Drug, pubmed-meshheading:20461382-Female, pubmed-meshheading:20461382-Humans, pubmed-meshheading:20461382-Imidazoles, pubmed-meshheading:20461382-Infusions, Intravenous, pubmed-meshheading:20461382-Male, pubmed-meshheading:20461382-Middle Aged, pubmed-meshheading:20461382-Pancreatic Neoplasms, pubmed-meshheading:20461382-Survival, pubmed-meshheading:20461382-Thioredoxins, pubmed-meshheading:20461382-Treatment Outcome
pubmed:year	2011
pubmed:articleTitle	A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination.
pubmed:affiliation	Virgina G Piper Cancer Center, TGen, Scottsdale, AZ, 85259, USA. rramanathan@tgen.org
pubmed:publicationType	Journal Article, Comparative Study, Randomized Controlled Trial, Clinical Trial, Phase II, Research Support, N.I.H., Extramural